摘要
目的探究妥布霉素雾化吸入治疗联合氨溴索在稳定期支气管扩张疾病治疗工作中的临床应用效果。方法回顾性分析2018年4月至2019年9月在我院接受诊治的82例稳定期支气管扩张患者的临床资料,用奇偶法将研究对象的临床资料平均分成对照组和研究组,每组患者41例,对照组实施妥布霉素雾化吸入治疗,研究组在对照组的基础上联合使用氨溴索治疗,两组的治疗时间均为6个月,对比两组患者的临床治疗效果以及气促、湿音、哮鸣音以及喘息等症状的改善时间和肺功能改善情况。结果经过为期6个月的治疗和干预,研究组患者的临床治疗有效率(97.56%)明显高于对照组(75.60%),P<0.05,研究结果具存在统计学意义。组间差异明显,研究具有统计学意义(P<0.05),且研究组患者的气促、湿音、哮鸣音以及喘息等症状的改善时间分别是(4.88±1.04)、(4.54±1.47)、(4.69±1.23)、(5.28±1.31),与对照组相比时间更短,组间差异明显,P<0.05;研究组患者治疗后PEF、FVC和FEV1等肺功能指标分别是(4.66±0.53)、(2.57±0.44)、(1.81±0.33),优于对照组,P<0.05。结论妥布霉素雾化吸入联合氨溴索的治疗方法在稳定期支气管扩张症患者中有较高的临床治疗效果,值得进一步推广使用。
Objective To explore the clinical effect of tobramycin aerosol inhalation combined with ambroxol in the treatment of stable bronchiectasis.Methods The clinical data of 82 patients with stable bronchiectasis who were treated in our hospital from April 2018 to September 2019 were analyzed retrospectively.The clinical data of the subjects were divided into control group and study group with parity method,41 patients in each group were treated with tobramycin aerosol inhalation in the control group.The study group was treated with ambroxol on the basis of the control group.The treatment time was 6 months.The clinical effect,the improvement time of shortness of breath,moist rale,wheezing and wheezing and the improvement of lung function were compared between the two groups.Results After 6 months of treatment,the effective rate of clinical treatment in the study group was 97.56%,and that in the control group was 75.60%.There was a significant difference between the two groups.The study was statistically significant(P<0.05),and the improvement time of dyspnea,rales,wheezing and wheezing in the study group was(4.88±1.04),(4.54±1.47),(4.69±1.23),respectively.Compared with the control group,PEF,FVC and FEV1 were(4.66±0.53),(2.57±0.44),(1.81±0.33)in the study group,which were better than those in the control group(P<0.05).Conclusion Tobramycin atomization combined with ambroxol has a higher clinical effect in stable stage of bronchiectasis,which is worth further promotion.
作者
沈晓蕾
SHEN Xiao-lei(Department of Critical Medicine,Dalian Fourth People's Hospital,Dalian 116031,China)
出处
《中国医药指南》
2020年第17期62-63,共2页
Guide of China Medicine
